ArticleNeuro-oncology advances
TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Giant Cell Glioblastoma: Case Series of a Rare Glioma with Unique Histomorphology and Molecular Heterogeneity.Asian journal of neurosurgery · 2026Article
- Patient-derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones.Brain pathology (Zurich, Switzerland) · 2026Article
- Article
- Article
- Case Report: Glioblastoma in cohabiting partners: a molecularly characterized temporal cluster.Frontiers in oncology · 2026Article
- Spectral discrimination of pediatric SF188 and adult glioblastoma stem cells by deep learning-enhanced Raman profiling.Frontiers in oncology · 2026Article
- The Gut-Brain Axis in Brain Tumors: Insights into Tumor Development, Progression, and Therapy.Biomedicines · 2025Review
- Spinal cord metastasis in a long-term survivor of primary malignant glioblastoma: A case report.Oncology letters · 2025Article
- Potential Diagnostic and Clinical Significance of Selected Genetic Alterations in Glioblastoma.International journal of molecular sciences · 2024Review
- "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.Acta neuropathologica · 2023Article
- An immune signature to predict the prognosis ofAging · 2023Article
- Ultra High-plex Spatial Proteogenomic Investigation of Giant Cell Glioblastoma Multiforme Immune Infiltrates Reveals Distinct Protein and RNA Expression Profiles.Cancer research communications · 2023Article
- pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.Histopathology · 2022Article
- DAXX-ATRX regulation of p53 chromatin binding and DNA damage response.Nature communications · 2022Article
- Morphogenetic and Imaging Characteristics in Giant Cell Glioblastoma.Current oncology (Toronto, Ont.) · 2022Article
- IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.Acta neuropathologica communications · 2021Article
- SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- TERT promoter mutation in sebaceous neoplasms.Virchows Archiv : an international journal of pathology · 2021Article
- p53-intact cancers escape tumor suppression through loss of long noncoding RNA Dino.Cell reports · 2021Article
- Glioblastoma multiforme: a multi-omics analysis of driver genes and tumour heterogeneity.Interface focus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell glioblastoma (gcGBM) is a rare morphological variant of IDH-wildtype (IDHwt) GBM that occurs in young adults and have a slightly better prognosis than "classic" IDHwt GBM.
methodsWe studied 36 GBMs, 14 with a histopathological diagnosis of gcGBM and 22 with a giant cell component. We analyzed the genetic profile of the most frequently mutated genes in gliomas and assessed the tumor mutation load (TML) by gene-targeted next-generation sequencing. We validated our findings using The Cancer Genome Atlas (TCGA) data.
resultsp53 was altered by gene mutation or protein overexpression in all cases, while driver
conclusionsgcGBMs have molecular features that contrast to "classic" IDHwt GBMs: unusually frequent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.